For many women diagnosed with endometrial (uterine) cancer, surgery is often the first and most important step in treatment.
Traditionally, many patients believed that once the uterus was removed, cancer treatment was complete. However, modern cancer care now focuses not only on removing the tumor but also on determining whether cancer has spread microscopically to nearby lymph nodes.
This is where Sentinel Lymph Node Biopsy and fluorescence-guided surgery are transforming the management of endometrial cancer worldwide.
In the past, surgeons commonly removed multiple pelvic lymph nodes to evaluate whether cancer had spread beyond the uterus.
While this approach helped with cancer staging, extensive lymph node removal could sometimes lead to complications such as leg swelling (lymphedema), numbness, pain, and a longer recovery period.
Advances in minimally invasive gynecologic oncology have introduced a more targeted approach known as Sentinel Lymph Node Mapping.
Sentinel lymph nodes are the first lymph nodes where cancer cells are most likely to spread.
Using SPY-PHI technology integrated with the Stryker 1788 fluorescence imaging platform, surgeons can visualize lymphatic pathways in real time through near-infrared fluorescence imaging.
This technique helps identify and evaluate only the most relevant lymph nodes, reducing the need for extensive lymph node removal in appropriately selected patients.
Removing the uterus alone may not always provide complete information about whether cancer has spread microscopically.
Sentinel lymph node biopsy can improve staging accuracy while minimizing surgical trauma and reducing the risk of long-term complications.
The goal of modern cancer surgery is not simply to remove more tissue, but to achieve greater precision with fewer side effects.
“The future of cancer surgery is not larger operations—it is smarter, more precise surgery.”
Sentinel lymph node biopsy is increasingly incorporated into modern gynecologic oncology guidelines and is recognized by leading cancer organizations worldwide.
With the availability of SPY-PHI fluorescence-guided imaging and advanced minimally invasive surgical techniques, precision oncology continues to redefine the future of endometrial and uterine cancer care.